Agilent has finalized the acquisition of BioTek Instruments in an all-cash transaction, a maneuver designed to fundamentally expand its capabilities in the critical cell analysis technology sector. The strategic rationale for this transaction centers on a "workflow-simplification" play, merging the target's industry-leading expertise in microplate detection and imaging with the group’s established presence in live-cell, real-time analysis. This structural alignment provides the organization with the scientific talent and technological hardware required to address the increasing complexity of immunotherapy and biologics research. This operation allows the group to execute a definitive structural expansion of its biopharma and academic service offerings.

This transaction is part of the Industry & Manufacturing industry, which currently tracks an average EBITDA multiple of 10.5x since the beginning of 2026, 3.1% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.